Literature DB >> 8788291

High- versus low-lipase acid-resistant enzyme preparations in cystic fibrosis: a crossover randomized clinical trial.

L Lancellotti1, G Cabrini, L Zanolla, G Mastella.   

Abstract

High-strength pancreatic enzyme preparations have recently come into widespread use in some countries for treatment of pancreatic insufficiency in cystic fibrosis. However, the therapeutic equivalence of these preparations to the standard acid-resistant microsphere preparations, under the same lipase dosage, has not been demonstrated by appropriate clinical trials; they are also considered responsible for severe colonic stricture. In a randomized crossover study, 20 adolescent or adult cystic fibrosis patients were treated in hospital with both low-lipase (A) and high-lipase (B) enteric-coated microsphere preparations. The fat excretion coefficient, evaluated over two 72-h fat balance periods (measured fat intake, 1.43 to 3 g/kg/day according to age), was the main response variable, secondary variables being stool wet and dry weight, fecal nitrogen output, and energy loss. With both preparations, patients were given a daily dose of 1,500-2,000 lipase BP U/g fat ingested, distributed across four meals. The low-strength preparation was divided into three doses during each meal, while the high-strength preparation was taken as a single dose in the middle of each meal. The considerable variability of results did not provide conclusive evidence of equivalence or significant differences between the two preparations in terms of steatorrhea and other variables. However, mean differences between the two treatments and their 95% confidence intervals showed less satisfactory results with the high-lipase preparation. A high-strength preparation is thought to release relatively less enzyme activity in the small intestine, forcing patients to increase their dosage and possibly creating a dangerous enzyme hyperconcentration in the large intestine. For this reason, the occasional occurrence of colonic stricture should be borne in mind, as must the possible scope for division of dosage during each meal.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8788291     DOI: 10.1097/00005176-199601000-00012

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  3 in total

Review 1.  Uses and abuses of enzyme therapy in cystic fibrosis.

Authors:  P Durie; D Kalnins; L Ellis
Journal:  J R Soc Med       Date:  1998       Impact factor: 5.344

Review 2.  Timing of pancreatic enzyme replacement therapy (PERT) in cystic fibrosis.

Authors:  Christabella Ng; Giles Major; Alan R Smyth
Journal:  Cochrane Database Syst Rev       Date:  2021-08-02

3.  Pancreatic enzyme replacement therapy for people with cystic fibrosis.

Authors:  Usha Rani R Somaraju; Arturo Solis-Moya
Journal:  Cochrane Database Syst Rev       Date:  2020-08-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.